Mirabegron XR Shortage Update: What Patients Need to Know in 2026

If your Mirabegron XR prescription is suddenly hard to fill in 2026, you deserve a clear explanation of what is happening and — more importantly — what you can do about it. This page provides an up-to-date look at the availability situation for Mirabegron XR (Myrbetriq), including the two key factors affecting access and practical next steps for patients.

The Official Status: Not on the FDA Shortage List

As of 2026, Mirabegron XR is not listed on the FDA's official drug shortage database. Brand-name Myrbetriq, manufactured by Astellas Pharma and distributed nationwide, is generally available at most pharmacies. If your pharmacy has brand-name Myrbetriq in stock, you may be able to get your prescription filled — though the cost without insurance or savings programs is high ($450 to $625 per month for a 30-day supply).

However, "not officially in shortage" is very different from "easy to find." Patients are experiencing real access challenges due to two distinct problems, each requiring a different solution.

Problem 1: Generic Mirabegron Supply Disrupted by Patent Litigation

The first generic version of Myrbetriq was approved by the FDA in September 2022, when Lupin Pharmaceuticals received clearance after Astellas's key patent expired. Multiple other manufacturers — Zydus, Alkem, Aurobindo, and Sawai USA — also received approvals, giving the market several sources of generic mirabegron extended-release.

Then, in April 2025, a federal court issued an injunction blocking Lupin and Zydus from selling their generic products due to patent infringement claims. These two companies were among the most significant suppliers in the generic mirabegron market. Their removal created immediate gaps in pharmacy inventory, and since pharmacies typically contract with specific wholesalers, switching suppliers is not instantaneous.

As of 2026, generic mirabegron from Alkem and other remaining manufacturers is available, but not uniformly stocked. One pharmacy may have it, while another across town is completely out. The generic supply situation could improve if the litigation resolves or if remaining manufacturers scale up production — but no resolution timeline has been made public.

Problem 2: Insurance Step Therapy Requirements (Effective November 2025)

Starting in November 2025, major health insurers including UnitedHealthcare began requiring step therapy for mirabegron. Under step therapy (also called "fail first"), your insurance plan requires that you try and fail on two alternative OAB medications — typically anticholinergics like oxybutynin or tolterodine — before your plan will approve and cover Mirabegron XR.

This policy affects patients who are newly starting OAB treatment, as well as some existing patients who were switched to plans with this requirement at open enrollment. Patients with commercial insurance and some Medicare Advantage plans may be impacted. Medicare Part D standard plans have varying coverage depending on the specific plan's formulary.

Who Is Most Affected?

Generic mirabegron users: Most likely to face pharmacy stock issues due to the patent litigation supply disruption.

Newly prescribed patients (UnitedHealthcare and similar plans): May have insurance deny coverage until step therapy requirements are met.

Elderly patients: May be particularly affected because they are often prescribed mirabegron specifically to avoid anticholinergic cognitive effects — the very drugs step therapy now requires them to try first.

Patients in rural or small-town areas: Fewer pharmacies means fewer chances to find generic stock.

38,912+ patients found their medications in stock

38K+

Find Mirabegron XR In Stock Today →

What Can Patients Do Right Now?

Here is a clear action plan depending on which problem you're facing:

If Your Pharmacy Is Out of Stock:

Use medfinder — a paid service that calls local pharmacies on your behalf and texts you which ones have Mirabegron XR in stock.

Ask your pharmacy if they can order it — most can have it within 1-3 business days through a different distributor.

Ask specifically about brand-name Myrbetriq if generic is unavailable — then use the Astellas Momentum Savings Card to reduce cost.

Try independent pharmacies and different chain pharmacies — each may carry different generic manufacturers.

Skip the calls, skip the stress.

Find Mirabegron XR In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

If Your Insurance Isn't Covering It:

Ask your doctor to submit a prior authorization (PA) exception. Your doctor can document why you medically need Mirabegron XR — especially if anticholinergic medications are contraindicated or you have a history of intolerance.

Use GoodRx or SingleCare coupons to pay cash price for generic mirabegron while your PA is processed — as low as $121 per month.

Check eligibility for the Astellas Patient Assistance Program if you are uninsured or underinsured.

Looking Ahead

The long-term outlook depends largely on how the patent litigation resolves and whether major insurers revise their step therapy policies. For now, the most effective approach is a combination of searching broadly for available stock (using tools like medfinder) and working with your prescriber on insurance appeals. For more practical tactics, see our guide on how to find Mirabegron XR in stock near you.